Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$5.95 - $15.79 $5.41 Million - $14.4 Million
-909,244 Reduced 18.8%
3,926,407 $61.9 Million
Q3 2023

Nov 14, 2023

SELL
$7.22 - $10.05 $718,166 - $999,663
-99,469 Reduced 2.02%
4,835,651 $37.5 Million
Q2 2023

Aug 14, 2023

BUY
$4.89 - $10.57 $1.31 Million - $2.83 Million
267,735 Added 5.74%
4,935,120 $49 Million
Q1 2023

May 15, 2023

BUY
$5.62 - $11.51 $1.15 Million - $2.35 Million
203,860 Added 4.57%
4,667,385 $27.1 Million
Q4 2022

Feb 14, 2023

BUY
$2.32 - $10.97 $2.66 Million - $12.6 Million
1,148,465 Added 34.64%
4,463,525 $35.4 Million
Q3 2022

Nov 14, 2022

BUY
$3.09 - $9.21 $10.2 Million - $30.5 Million
3,315,060 New
3,315,060 $10.5 Million

Others Institutions Holding ICVX

About Icosavax, Inc.


  • Ticker ICVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,885,200
  • Description
  • Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...
More about ICVX
Track This Portfolio

Track T. Rowe Price Investment Management, Inc. Portfolio

Follow T. Rowe Price Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.